Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06408142
Other study ID # IRB00443103
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2024
Est. completion date September 1, 2027

Study information

Verified date May 2024
Source Johns Hopkins University
Contact David Rudolph, MD
Phone 3195419183
Email drudolp3@jhmi.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this study is to determine how many patients with HIV or at high risk of getting HIV attend the Emergency Department (ED) in South Africa (SA). the investigators will integrate HIV assessment in the ED and see how many people who would be a candidate for a drug that prevents HIV (PrEP). Universal test and connect (UTC) is a strategy that universally tests all patients and connects patients to long-term care, whether HIV positive or negative, including referrals for PrEP. The investigator's goal is to use UTC across two busy 24-hr EDs in Cape Town, SA.


Description:

The overarching goal of this proposal is to deliver comprehensive HIV services for patients with HIV or at high risk of HIV acquisition attending the Emergency Department (ED) in South Africa (SA). The investigators seek to integrate HIV assessment in the ED and define the opportunity for delivering biomedical HIV prevention interventions in this setting. In SA, a high proportion of people living with HIV (PLHIV) receive care in the ED: 25% of ED patients are living with HIV, and of these only 45% are on ART (compared to 75% nationally); 7% of ED patients with HIV have not previously been diagnosed. The EDs provide care to high volumes of adults who may not otherwise interact with the health system, and thus are an important testing and linkage to care venue. Access to both preventative (pre- and post-exposure prophylaxis) and therapeutic (ART (antiretroviral) initiation) HIV services from the ED can expand care to otherwise missed populations and aligns directly with a differentiated service delivery model that is integrated within existing, sustainable service delivery models. Universal test and connect (UTC) is a holistic strategy that endeavors to accelerate the race to reduce new HIV infections and deaths from AIDS-related illnesses. Trials in Africa have shown that within three years of implementing a community-wide UTC program, HIV incidence decreased by 20-30%, and AIDS-related mortality decreased by 20% . This strategy resulted in increased diagnosis among men and provided preventative resources to young women. Given ED patients' vulnerabilities and lack of access to routine services, UTC is a new and needed tool to provide comprehensive ED-based HIV services. Currently, testing is haphazard, and while occupational exposure may be addressed, preventative strategies for other high-risk exposures are not. The investigators seek to demonstrate that the ED has a high volume of patients that could potentially benefit from HIV services (i.e., HIV testing, ART initiation, pre-exposure prophylaxis (PrEP)/post-exposure prophylaxis (PEP) initiation, and linkage to care) and that HIV service delivery in this venue is necessary and feasible to integrate. Furthermore, the investigators seek to explore the missed opportunity to deliver PrEP in the ED, thus expanding PrEP access to all segments of the population. The investigators propose to demonstrate that PrEP initiation in the ED is an important investment to providing holistic care for ED patients and that providers will be accepting of ED-based PrEP delivery if HIV testing and PrEP initiation can be effectively integrated into clinical workflow.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1573
Est. completion date September 1, 2027
Est. primary completion date September 1, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - Patients attending the Emergency Department - Ages > or = 12 years old Exclusion Criteria: - Patients unable to provide written informed consent - i.e., have a depressed level of consciousness (head trauma or concurrent alcohol/substance abuse), determined as critically ill (triage score of "emergent"), or - do not speak a language spoken by the study team (English, Afrikaans, and Xhosa).

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
HIV testing
Point of Care HIV testing universally regardless of risk factors

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Johns Hopkins University Desmond Tutu HIV Foundation, National Institutes of Health (NIH)

Outcome

Type Measure Description Time frame Safety issue
Primary The proportion of potentially PrEP eligible patients in the ED Baseline survey, chart abstraction, and use of South Africa National Department of Health PrEP Eligibility Guidelines Baseline
Secondary The number of potentially PrEP eligible patients with tuberculosis or acute HIV Lab testing obtained through medical record Baseline
Secondary The number of potentially PrEP eligible patients with renal dysfunction Lab testing obtained through medical record Baseline
Secondary The number of potentially PrEP eligible patients who report baseline difficulty to engage in follow up required to be on PrEP Social Determinants of Health Survey including financial insecurity (1-5), food insecurity (two questions, one 1-4 and the other 1-5), transportation needs (yes vs no as need for transportation within past 12 months), physical activity level (days per week of exercise and average exercise time per exercise session), stress (1-5), social connections (1-5), substance use (number of drinks or use off illicit substances used per week), intimate partner violence (Number of instances in past 12 months). Scored on subscales, parentheses indicating Likert scores with lower scores indicating worse outcome Baseline
See also
  Status Clinical Trial Phase
Terminated NCT03516318 - Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria N/A
Completed NCT04653194 - Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat' Phase 3
Completed NCT01792570 - DRV/r + RPV QD: Efficacy and Toxicity Reduction Phase 3
Active, not recruiting NCT04826562 - Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND) Phase 4
Completed NCT04191967 - Thermocoagulation for Treatment of Precancerous Cervical Lesions N/A
Completed NCT02812329 - Intervention to Encourage HIV Testing and Counseling Among Adolescents Phase 1
Completed NCT02919306 - Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults Phase 1/Phase 2
Completed NCT02651376 - Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients Phase 1/Phase 2
Completed NCT02516930 - A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China N/A
Recruiting NCT02392884 - HIV Medication Adherence in Underserved Populations N/A
Completed NCT01944371 - Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study Phase 1/Phase 2
Recruiting NCT01778374 - Mater-Bronx Rapid HIV Testing Project. N/A
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT01460433 - Problems With Immune Recovery in the Gut Tissue N/A
Completed NCT01076179 - Kaletra in Combination With Antiretroviral Agents N/A
Completed NCT01490346 - Tissue Drug Levels of HIV Medications N/A
Completed NCT00317460 - Buprenorphine and Integrated HIV Care Phase 4
Terminated NCT04240210 - Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita) Phase 4
Active, not recruiting NCT04704336 - Integration of Hypertension Management Into HIV Care in Nigeria N/A
Completed NCT03254277 - 3BNC117-LS First-in-Human Phase 1 Study Phase 1